鼻内镜手术后使用布地奈德鼻喷雾剂治疗慢性鼻-鼻窦炎伴变应性鼻炎的临床观察

发布时间：2018-03-14 12:18

本文选题：变应性鼻炎　切入点：慢性鼻-鼻窦炎　出处：《中国药房》2017年02期 　论文类型：期刊论文

【摘要】：目的:探讨鼻内镜手术后使用布地奈德鼻喷雾剂治疗慢性鼻-鼻窦炎伴变应性鼻炎的临床疗效及安全性。方法:将120例慢性鼻-鼻窦炎伴变应性鼻炎患者按随机数字表法分为对照组和试验组,各60例。两组患者均行鼻内镜手术。对照组患者术毕1周后给予生理盐水灌洗鼻腔;试验组患者术毕1周后给予布地奈德鼻喷雾剂喷鼻,早晚各1次。两组患者疗程均为3个月。比较两组患者治疗前后变应性鼻炎相关症状评分及临床疗效,利用光镜和电镜对鼻腔黏膜的超微结构进行观察,并统计不良反应发生情况。结果:治疗前,两组患者变应性鼻炎症状评分比较,差异无统计学意义(P0.05);治疗后,两组患者变应性鼻炎症状评分显著降低,且试验组显著低于对照组,差异均有统计学意义(P0.05)。试验组患者临床总有效率为94.83%,明显高于对照组的50.00%,差异有统计学意义(P0.05)。两组患者治疗后鼻腔黏膜病理性腺体增生及黏膜水肿均明显改善,差异有统计学意义(P0.05),但组间比较,差异无统计学意义(P0.05)。试验组患者鼻腔黏膜修复时间(3个月)显著短于对照组(6个月),差异有统计学意义(P0.05)。两组患者不良反应发生率比较,差异无统计学意义(P0.05)。结论:鼻内镜手术后使用布地奈德鼻喷雾剂治疗慢性鼻-鼻窦炎伴变应性鼻炎疗效显著,能明显改善患者变应性鼻炎相关症状,修复鼻腔黏膜的超微结构,且安全性较好。
[Abstract]:Objective: to investigate the clinical efficacy and safety of budesonide nasal spray in the treatment of chronic rhinosinusitis with allergic rhinitis after endoscopic sinus surgery. Methods: 120 cases of chronic rhinosinusitis with allergic rhinitis were randomly divided into two groups. The digital table method was divided into two groups: the control group and the experimental group. 60 patients in each group were treated with endoscopic sinus surgery. The patients in the control group were given saline lavage one week after operation, and the patients in the test group were given budesonide nasal spray 1 week after operation. The course of treatment was 3 months in both groups. The scores of symptoms and clinical efficacy of allergic rhinitis before and after treatment were compared, and the ultrastructure of nasal mucosa was observed by light microscope and electron microscope. Results: before treatment, the scores of allergic rhinitis in the two groups had no significant difference (P 0.05), but after treatment, the scores of allergic rhinitis in the two groups were significantly lower than those in the control group. The experimental group was significantly lower than the control group. The total effective rate of the patients in the trial group was 94.83, which was significantly higher than that in the control group (50.005%). The difference was statistically significant (P 0.05). After treatment, the nasal mucosal pathological gland hyperplasia and mucosal edema were significantly improved in the two groups. The difference was statistically significant (P 0.05), but there was no significant difference between the two groups (P 0.05). The nasal mucosal repair time (3 months) in the trial group was significantly shorter than that in the control group (6 months), and the difference was statistically significant (P 0.05). The incidence of adverse reactions in the two groups was higher than that in the control group. Conclusion: budesonide nasal spray is effective in the treatment of chronic rhinosinusitis associated with allergic rhinitis, and can improve the symptoms of allergic rhinitis and repair the ultrastructure of nasal mucosa. And the safety is good.
【作者单位】：重庆市中医院耳鼻喉科;
【基金】：重庆市卫生局中医药科技项目(No.2012-2-171)
【分类号】：R765.9

【相似文献】